← Back to Search

Other

Diet + Lovastatin + Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis

Phase 2
Waitlist Available
Research Sponsored by National Center for Research Resources (NCRR)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
PROTOCOL ENTRY CRITERIA: Cerebrotendinous xanthomatosi
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial will study patients with cerebrotendinous xanthomatosis to see the effects of a cholesterol- and cholestanol-free diet, and the drugs lovastatin and chenodeoxycholic acid, on the biosynthesis of cholesterol and cholestanol, and the turnover of individual sterols and bile acids.

Who is the study for?
This trial is for patients who have been diagnosed with cerebrotendinous xanthomatosis, a rare condition affecting cholesterol and bile acid metabolism. Participants need to follow a special diet free from cholesterol and cholestanol.
What is being tested?
The study aims to see how a diet without cholesterol and cholestanol, along with medications lovastatin and chenodeoxycholic acid, affects the body's production of these substances in people with cerebrotendinous xanthomatosis.
What are the potential side effects?
Potential side effects may include muscle pain or weakness due to lovastatin, as well as digestive issues like stomach pain or constipation from both treatments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

National Center for Research Resources (NCRR)Lead Sponsor
537 Previous Clinical Trials
317,011 Total Patients Enrolled
Oregon Health and Science UniversityOTHER
985 Previous Clinical Trials
7,385,719 Total Patients Enrolled
William ConnorStudy ChairOregon Health and Science University
2 Previous Clinical Trials
105 Total Patients Enrolled

Media Library

Cholesterol- and Cholestanol-Free Diet (Other) Clinical Trial Eligibility Overview. Trial Name: NCT00004346 — Phase 2
Cerebrotendinous Xanthomatosis Research Study Groups:
Cerebrotendinous Xanthomatosis Clinical Trial 2023: Cholesterol- and Cholestanol-Free Diet Highlights & Side Effects. Trial Name: NCT00004346 — Phase 2
Cholesterol- and Cholestanol-Free Diet (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00004346 — Phase 2
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top